Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DG6V7E
|
|||
Drug Name |
GS-1423
|
|||
Synonyms |
AGEN 1423
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
Agenus; Gilead Sciences
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Ecto-5'-nucleotidase (CD73) | Target Info | . | [2] |
Transforming growth factor beta (TGFB) | Target Info | . | [2] | |
BioCyc | Purine nucleotides degradation | |||
Urate biosynthesis/inosine 5'-phosphate degradation | ||||
Adenosine nucleotides degradation | ||||
KEGG Pathway | Purine metabolism | |||
Pyrimidine metabolism | ||||
Nicotinate and nicotinamide metabolism | ||||
Metabolic pathways | ||||
Panther Pathway | Purine metabolism | |||
Pyrimidine Metabolism | ||||
Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
Reactome | Purine catabolism | |||
WikiPathways | Differentiation Pathway | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase | ||||
Metabolism of nucleotides |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03954704) Study of GS-1423 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Agenus. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.